Literature DB >> 2899603

Idiotype vaccines against human T cell leukemia. II. Generation and characterization of a monoclonal idiotype cascade (Ab1, Ab2, and Ab3).

M Bhattacharya-Chatterjee1, S K Chatterjee, S Vasile, B K Seon, H Kohler.   

Abstract

Previously, we had generated anti-Id mAb (Ab2) binding to a hybridoma SN2 (Ab1), which recognizes a glycoprotein, gp37, expressed by human leukemic T cells. To characterize these anti-idiotopes further, they were used to immunize mice and rabbits. Several murine anti-anti-Idiotype mAb (Ab3), mostly of IgM-k isotype, were obtained. mAb3 and sera from rabbits immunized with Ab2 contained antibodies that bind to gp37 Ag and leukemic MOLT-4 and JM cells. Also, mAb3 and immune sera from rabbits competed with Ab1 for binding to MOLT-4 cells. They inhibited the binding of iodinated Ab1 to Ab2 indicating that Ab3 in mice and rabbits shares idiotopes with Ab1 (SN2). Furthermore, both the murine mAb3 and rabbit polyclonal Ab3 immunoprecipitated the same gp37 Ag as SN2 (Ab1). The production of Ag-specific Ab3 (Ab1') in mice and rabbits in absence of any exposure to gp37 indicates that these Ab2 may indeed carry the internal image of the gp37 Ag. Such anti-idiotopes (Ab2 beta) may be useful as Ag substitute for the induction of therapeutic immunity in T cell leukemia patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2899603

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Maintenance of antigen-specific immunological memory through variable regions of heavy and light chains of anti-idiotypic antibody.

Authors:  J Vani; R Nayak; M S Shaila
Journal:  Immunology       Date:  2007-01-11       Impact factor: 7.397

2.  Idiotype network components are involved in the murine immune response to simian virus 40 large tumor antigen.

Authors:  R L Mernaugh; M H Shearer; R K Bright; R E Lanford; R C Kennedy
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 3.  Idiotypic antibody immunotherapy of cancer.

Authors:  M B Chatterjee; K A Foon; H Köhler
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

4.  Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine.

Authors:  K A Foon; M Chakraborty; W J John; A Sherratt; H Köhler; M Bhattacharya-Chatterjee
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

5.  Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice.

Authors:  M Coelho; P Gauthier; M Pugnière; F Roquet; A Pèlegrin; I Navarro-Teulon
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.